The Amyloidosis Research Consortium (ARC) addresses critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. We have created a collaborative research model to bring together experts in the field to address the challenges that exist in developing ...
The Amyloidosis Research Consortium (ARC) addresses critical needs in clinical trials and related research for the underserved group of systemic amyloid diseases. We have created a collaborative research model to bring together experts in the field to address the challenges that exist in developing diagnostic tools and to carrying out innovative clinical trials.
Stay up to date with the latest news and research from ARC's newsletter: http://www.arci.org/newsletter-sign-up
ARC is committed to building collaborative relationships between patients, academia, industry, foundations, federal funders, and regulators to advance the best research and speed new therapies to market.
ARC is focused on increasing the amount of research and building a prioritized portfolio of translational research and clinical research.
The work of the Amyloidosis Research Consortium has been made possible through the generous support of our donors. With continued funding of our strategic and vital research programs, you are investing in a promising future for amyloidosis patients. You can donate here: www.arci.org/donate
